Literature DB >> 7660300

Ocular surface squamous neoplasia.

G A Lee1, L W Hirst.   

Abstract

Ocular surface squamous neoplasia presents as a spectrum from simple dysplasia to carcinoma in situ to invasive squamous cell carcinoma involving the conjunctiva as well as the cornea. It is a distinct clinical entity, although it has been known by a variety of different names throughout the literature. Most commonly it arises in the limbal region, occurring particularly in elderly males who have lived in geographic areas exposed to high levels of ultraviolet-B radiation. Symptoms range from none to severe pain and visual loss. The development of preoperative diagnostic techniques, such as impression cytology, are of value in clinical decision making and follow-up management. Simple excision with adequate margins is currently the best established form of treatment despite trials of other modalities. The course of this disease may be evanescent, but is more frequently slowly progressive and may require exenteration and occasionally may lead to death.

Entities:  

Mesh:

Year:  1995        PMID: 7660300     DOI: 10.1016/s0039-6257(05)80054-2

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  147 in total

1.  Total regression of extensive conjunctival intraepithelial neoplasia with superficial corneal invasion treated with topical mitomycin C 0.02%.

Authors:  Marta Calatayud; Josep Badal; Laia Bisbe; Sara Martin; Javier Puig
Journal:  BMJ Case Rep       Date:  2009-12-03

2.  The clinical value of in vivo confocal microscopy for diagnosis of ocular surface squamous neoplasia.

Authors:  Y Xu; Z Zhou; Y Xu; M Wang; F Liu; H Qu; J Hong
Journal:  Eye (Lond)       Date:  2012-03-09       Impact factor: 3.775

3.  Exenteration of invasive conjunctival squamous cell carcinoma.

Authors:  R Guthoff; W E Lieb; P Ströbel; A Zettl
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

Review 4.  Bilateral ocular surface squamous neoplasia: a clinicopathological case report.

Authors:  Y Usui; G O Waring; R F See; N A Rao; A C Marrone
Journal:  Br J Ophthalmol       Date:  2004-04       Impact factor: 4.638

5.  Superficial ocular malignancies treated with strontium-90 brachytherapy: long term outcomes.

Authors:  Siddhartha Laskar; Lavanya Gurram; Sarbani Ghosh Laskar; Suresh Chaudhari; Nehal Khanna; Rituraj Upreti
Journal:  J Contemp Brachytherapy       Date:  2015-10-16

6.  The correlation of routine tear function tests and conjunctival impression cytology in dry eye syndrome.

Authors:  Prachi Kumar; Rahul Bhargava; Manoj Kumar; Somesh Ranjan; Manjushri Kumar; Pratima Verma
Journal:  Korean J Ophthalmol       Date:  2014-03-14

7.  Whole exome profiling and mutational analysis of Ocular Surface Squamous Neoplasia.

Authors:  Nallely Ramos-Betancourt; Matthew G Field; Jesus H Davila-Alquisiras; Carol L Karp; Luis F Hernández-Zimbrón; Roberto García-Vázquez; Kristian A Vazquez-Romo; Gaofeng Wang; Jans Fromow-Guerra; Everardo Hernandez-Quintela; Anat Galor
Journal:  Ocul Surf       Date:  2020-07-24       Impact factor: 5.033

8.  Surgical versus Medical Treatment of Ocular Surface Squamous Neoplasia: A Cost Comparison.

Authors:  Christina S Moon; Afshan A Nanji; Anat Galor; Kathryn E McCollister; Carol L Karp
Journal:  Ophthalmology       Date:  2015-12-11       Impact factor: 12.079

Review 9.  Ultra high-resolution anterior segment optical coherence tomography in the diagnosis and management of ocular surface squamous neoplasia.

Authors:  Benjamin J Thomas; Anat Galor; Afshan A Nanji; Fouad El Sayyad; Jianhua Wang; Sander R Dubovy; Madhura G Joag; Carol L Karp
Journal:  Ocul Surf       Date:  2013-11-09       Impact factor: 5.033

10.  Identification of multiple DNA copy number alterations including frequent 8p11.22 amplification in conjunctival squamous cell carcinoma.

Authors:  Laura Asnaghi; Hind Alkatan; Alka Mahale; Maha Othman; Saeed Alwadani; Hailah Al-Hussain; Sabah Jastaneiah; Wayne Yu; Azza Maktabi; Deepak P Edward; Charles G Eberhart
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-09       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.